These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. In vitro activity of garenoxacin against recent clinical isolates of Chlamydia pneumoniae. Roblin PM; Reznik T; Hammerschlag MR Int J Antimicrob Agents; 2003 Jun; 21(6):578-80. PubMed ID: 12791473 [TBL] [Abstract][Full Text] [Related]
14. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe. Critchley IA; Jones ME; Heinze PD; Hubbard D; Engler HD; Evangelista AT; Thornsberry C; Karlowsky JA; Sahm DF Clin Microbiol Infect; 2002 Apr; 8(4):214-21. PubMed ID: 12047413 [TBL] [Abstract][Full Text] [Related]
15. Quality control guidelines for MIC susceptibility testing of NVP PDF-713: a novel peptide deformylase inhibitor. Anderegg TR; Biedenbach DJ; Jones RN; Int J Antimicrob Agents; 2003 Jul; 22(1):84-6. PubMed ID: 12842335 [No Abstract] [Full Text] [Related]
16. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. Roblin PM; Hammerschlag MR Antimicrob Agents Chemother; 1998 Jun; 42(6):1515-6. PubMed ID: 9624507 [TBL] [Abstract][Full Text] [Related]
17. In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae. Roblin PM; Reznik T; Kutlin A; Hammerschlag MR Antimicrob Agents Chemother; 1999 Nov; 43(11):2806-7. PubMed ID: 10543770 [TBL] [Abstract][Full Text] [Related]
18. Commercial broth microdilution panel validation and reproducibility trials for NVP PDF-713 (LBM 415), a novel inhibitor of bacterial peptide deformylase. Fritsche TR; Moet GJ; Jones RN Clin Microbiol Infect; 2004 Sep; 10(9):857-60. PubMed ID: 15355422 [TBL] [Abstract][Full Text] [Related]